TD Cowen raised the firm’s price target on NeoGenomics (NEO) to $12 from $10 and keeps a Buy rating on the shares after hosting meetings with management. The firm left more constructive on NeoGenomics’s new product launches, saying MolDX reimbursement remains the “final gate” for a 2026 ramp.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics Buy Rating: Strategic Product Launches and Management Changes Drive Growth Potential
- NeoGenomics price target raised to $11 from $6.50 at Stephens
- Dell reports ‘beat and raise,’ Caterpillar sees big tariff impacts: Morning Buzz
- NeoGenomics’ Legal Victory and Market Potential Boosts Buy Rating
- NeoGenomics announces court ruling in its favor in lawsuit against Natera